Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 7:36 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 383,148 6.700% | 38,860 (+11.29%) | Filing History |
| 2024-02-14 4:44 pm Purchase | 2022-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ACORN BIOVENTURES, L.P. | 591,862 9.990% | 591,862 (New Position) | Filing History |
| 2024-02-14 4:32 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Lincoln Park Capital Fund LLC | 53,338 0.947% | -6,998 (-11.60%) | Filing History |
| 2024-02-13 6:55 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 563,859 11.000% | 157,109 (+38.63%) | Filing History |
| 2024-02-07 5:09 pm Sale | 2024-01-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 272,025 4.900% | -8,559 (-3.05%) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BlackRock Inc. BLK | 280,584 5.000% | 244,768 (+683.40%) | Filing History |
| 2024-01-16 4:18 pm Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Millennium Management LLC | 55,477 1.000% | -220,150 (-79.87%) | Filing History |
| 2024-01-08 10:26 am Sale | 2023-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management, LP | 151,654 2.650% | -54,969 (-26.60%) | Filing History |
| 2023-06-16 4:04 pm Purchase | 2023-06-09 | 13G | X4 Pharmaceuticals, Inc. XFOR | Millennium Management LLC | 275,627 5.200% | 275,627 (New Position) | Filing History |
| 2023-05-26 3:03 pm Purchase | 2023-05-18 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 524,760 9.990% | 120,200 (+29.71%) | Filing History |
| 2023-02-14 5:24 pm Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 344,288 8.200% | 283,077 (+462.46%) | Filing History |
| 2023-02-14 4:18 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 30,441 1.300% | -23,999 (-44.08%) | Filing History |
| 2023-02-14 11:26 am Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital, LLC | 11,638 0.300% | -63,845 (-84.58%) | Filing History |
| 2023-02-14 06:34 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Bain Capital Life Sciences Fund, L.P. | 406,750 11.000% | 310,532 (+322.74%) | Filing History |
| 2023-02-13 5:51 pm Sale | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | BIOTECHNOLOGY VALUE FUND L P | 75,280 1.900% | -25,642 (-25.41%) | Filing History |
| 2023-01-13 08:02 am Purchase | 2022-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Empery Asset Management, LP | 206,623 5.120% | 206,623 (New Position) | Filing History |
| 2022-12-19 5:31 pm Purchase | 2022-12-09 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 404,560 9.990% | 175,288 (+76.45%) | Filing History |
| 2022-07-19 5:28 pm Purchase | 2022-07-06 | 13D | X4 Pharmaceuticals, Inc. XFOR | Growth Equity Opportunities 18 VGE, LLC | 229,272 9.900% | 229,272 (New Position) | Filing History |
| 2022-02-14 4:43 pm Sale | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Ikarian Capital, LLC | 75,483 8.100% | -12,017 (-13.73%) | Filing History |
| 2022-02-14 4:38 pm Purchase | 2021-12-31 | 13G | X4 Pharmaceuticals, Inc. XFOR | Point72 Asset Management, L.P. | 54,440 5.800% | 4,432 (+8.86%) | Filing History |